

CJC-1295 +
Ipamorelin Blend

QUALITY CONTROL CERTIFICATE

CJC-1295 + Ipamorelin acetate blend



Certificate No.
CP-QCC-2026-055952

Lot Number
CJCIPM-MAY26-6L3ONX

Release Date
2026.05.20

PRODUCT INFORMATION

Product Name	CJC-1295 + Ipamorelin Blend
Dosage Form	Lyophilized powder (reconstitute before use)
Total Peptide Content	10 mg per vial (CJC-1295: 5 mg + Ipamorelin: 5 mg)
Appearance	White to off-white lyophilized cake/powder
Solubility	Freely soluble in bacteriostatic water or sterile water
Storage	Refrigerate 2-8 C; protect from light
Intended Use	Laboratory research use only - not for human consumption

COMPOSITION REFERENCE

CJC-1295 with DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-DAC

Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Peptide sequence records for identity verification purposes

QUALITY CONTROL TEST RESULTS

Test	Method	Specification	Result	Status
Appearance	Visual	White lyophilized cake	Conforms	PASS
Identity (CJC-1295)	HPLC/MS	Matches reference	Confirmed	PASS
Identity (Ipamorelin)	HPLC/MS	Matches reference	Confirmed	PASS
Purity (CJC-1295)	HPLC	>= 98.0%	99.1%	PASS
Purity (Ipamorelin)	HPLC	>= 98.0%	98.7%	PASS
Peptide Content	Gravimetric	Report result	12.04 mg	PASS
Endotoxin	USP <85> LAL	< 0.50 EU/mg	< 0.10 EU/mg	PASS
Sterility	USP <71>	No growth (14 days)	No growth	PASS

CERTIFICATION

This product has been manufactured, tested, and released in accordance with national quality standards. All tests performed meet or exceed applicable specifications.

RELEASED FOR DISTRIBUTION • LOT: CJCIPM-MAY26-6L3ONX • RELEASE DATE: 2026.05.20